BlackRock's reduction below 5% removes a large passive holder from the 5%+ roster, but as a routine portfolio adjustment by a passive asset manager, it does not signal a fundamental view on Zentalis. Monitor for further 13G filings from other large holders to gauge broader institutional sentiment.
Price Chart
Executive Summary
BlackRock Inc. filed an amended Schedule 13G disclosing a 4.1% passive stake in Zentalis Pharmaceuticals as of September 30, 2026, down from a prior 5%+ position. The filing indicates BlackRock crossed below the 5% threshold, reducing its holdings to 3,871,884 shares.
Key Financial Metrics
Key Facts
- BlackRock Inc. filed Schedule 13G/A on 2026-10-27, reporting 3,871,884 shares (4.1% of common stock) as of 2026-09-30.
- BlackRock previously held 5% or more of Zentalis common stock; the current filing shows a decrease below the 5% threshold.
- The filing is a passive investor update under Rule 13d-1(b); BlackRock disclaims any intent to change or influence control.
- Several BlackRock subsidiaries (BlackRock Advisors, BlackRock Fund Advisors, etc.) are listed as entities beneficially owning 5% or greater of the class.
Financial Impact
BlackRock reduced its stake from above 5% to 4.1%, representing a decrease of at least 0.9 percentage points of outstanding shares.
Risk Factors
- BlackRock's exit below 5% could precede further selling, though as a passive manager this is unlikely to be a conviction-driven move.
- No specific risk to Zentalis operations or financials from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0002012383-26-003868 |
| Document: Item_7.txt | 0002012383-26-003868 |
| Document: 0002012383-26-003868-index-headers.html | 0002012383-26-003868 |
| Document: 0002012383-26-003868-index.html | 0002012383-26-003868 |
| Document: 0002012383-26-003868.txt | 0002012383-26-003868 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 4d ago | SC 13G/A | $2.06 | awaiting T+60 | awaiting T+60 | $1.96 (−4.85%) |
Oct 18, 2026 13d ago | Press Release | $2.30 | awaiting T+60 | awaiting T+60 | $1.96 (−14.78%) |
Oct 1, 2026 4w ago | Press Release | $2.52 | awaiting T+60 | awaiting T+60 | $1.96 (−22.22%) |
Aug 14, 2026 11w ago | 8-K | $3.71 | awaiting T+60 | awaiting T+60 | $1.96 (+47.10%) |
Aug 13, 2026 11w ago | Press Release | $3.56 | awaiting T+60 | awaiting T+60 | $1.96 (+44.94%) |
Jun 11, 2026 20w ago | Institutional Cluster | $3.75 $4.03 | ▲ +7.47% | ▲ +4.20% | $1.96 (−47.73%) |
Jun 1, 2026 21w ago | Press Release | $3.95 $3.89 | ▼ −1.52% | ▼ −2.64% | $1.96 (−50.38%) |
May 21, 2026 23w ago | Press Release | $4.06 $3.68 | ▼ −9.36% | ▼ −12.55% | $1.96 (−51.72%) |
May 21, 2026 23w ago | 8-K | $4.06 $3.68 | ▼ −9.36% | ▼ −12.55% | $1.96 (−51.72%) |
May 12, 2026 24w ago | 8-K | No price | awaiting T+60 | awaiting T+60 | No price |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers